You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

tislelizumab

Showing 26 - 50 of 387
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Hepatocellular Carcinoma, Recurrence, Immune Checkpoint Inhibitor Trial in Nanning (Adjuvant tislelizumab plus lenvatinib,

Not yet recruiting
  • Hepatocellular Carcinoma
  • +2 more
  • Adjuvant tislelizumab plus lenvatinib
  • Adjuvant tislelizumab
  • Nanning, China
    Jian-Hong Zhong
Jun 11, 2023

Gastric Cancer Trial (Tislelizumab, 5Fu, Paclitaxel injection)

Not yet recruiting
  • Gastric Cancer
  • Tislelizumab
  • +2 more
  • (no location specified)
Feb 21, 2023

Nasopharyngeal Carcinoma Trial in Singapore (CCRT with Maintenance Tislelizumab and Metronomic Capecitabine)

Not yet recruiting
  • Nasopharyngeal Carcinoma
  • CCRT with Maintenance Tislelizumab and Metronomic Capecitabine
  • Singapore, Singapore
  • +1 more
Oct 16, 2023

Advanced Solid Tumor, Solid Tumor Trial (BGB-26808, Tislelizumab)

Not yet recruiting
  • Advanced Solid Tumor
  • Solid Tumor
  • (no location specified)
Aug 7, 2023

Non-Muscle Invasive Bladder Cancer, HER2 Trial (RC48, Tislelizumab)

Not yet recruiting
  • Non-Muscle Invasive Bladder Cancer
  • HER2
  • (no location specified)
Jul 16, 2023

Hepatocellular Carcinoma, Lenvatinib, Tislelizumab Trial in Hangzhou (TACE, Tislelizumab, Lenvatinib)

Not yet recruiting
  • Hepatocellular Carcinoma
  • +5 more
  • TACE
  • Tislelizumab, Lenvatinib
  • Hangzhou, Zhejiang, China
    1# Banshan East Rd. Zhejiang cancer hospital
Jun 17, 2023

Esophageal Squamous Cell Carcinoma Trial in Shantou (Tislelizumab)

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • Tislelizumab
  • Shantou, Guangdong, China
    Cancer Hospital of Shantou University Medical College
Aug 2, 2023

Esophageal Squamous Cell Carcinoma, Neoadjuvant Chemoimmunotherapy, Adjuvant Therapy Trial in Shanghai (Tislelizumab)

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • +2 more
  • Tislelizumab
  • Shanghai, Shanghai, China
    Shanghai chest hospital
Sep 24, 2023

Head and Neck Squamous Cell Carcinoma, Head Neck Cancer Trial (Tislelizumab, BGB-A425, LBL-007)

Not yet recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Head and Neck Cancer
  • Tislelizumab
  • +2 more
  • (no location specified)
Jun 9, 2023

Gastric or Gastroesophageal Junction Adenocarcinoma Trial in Nanjing (neoadjuvant chemo-hypofractionated radiotherapy plus PD-1

Active, not recruiting
  • Gastric or Gastroesophageal Junction Adenocarcinoma
  • neoadjuvant chemo-hypofractionated radiotherapy plus PD-1 antibody (Tislelizumab)
  • Nanjing, Jiangsu, China
    Jiangsu Cancer Hospital
Jul 4, 2023

Biliary Tract Carcinoma Trial in Beijing (Gemcitabine, S1, Tislelizumab)

Not yet recruiting
  • Biliary Tract Carcinoma
  • Beijing, China
    Chinese Academy of Medical Sciences & Peking Union Medical Colle
Apr 10, 2023

Gastric, Colorectal Adenocarcinoma Trial in Shenyang (tislelizumab)

Not yet recruiting
  • Gastric
  • Colorectal Adenocarcinoma
  • tislelizumab
  • Shenyang, Liaoning, China
    Liaoning Cancer Hospital & Institute
Nov 1, 2023

HER2-positive Gastric Cancer, Immunotherapy Trial in Shanghai (Disitamab Vedotin combined with fruquintinib and Tislelizumab)

Recruiting
  • HER2-positive Gastric Cancer
  • Immunotherapy
  • Disitamab Vedotin combined with fruquintinib and Tislelizumab
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Aug 8, 2023

Unresectable Hepatocellular Carcinoma, Oligometastatic Disease Trial in Beijing (SBRT plus tislelizumab and regorafenib)

Recruiting
  • Unresectable Hepatocellular Carcinoma
  • Oligometastatic Disease
  • SBRT plus tislelizumab and regorafenib
  • Beijing, Beijing, China
    Peking University Cancer Hospital
Jun 15, 2023

Non Small Cell Lung Cancer Trial (Tislelizumab, Ociperlimab, LBL-007)

Not yet recruiting
  • Non Small Cell Lung Cancer
  • Tislelizumab
  • +2 more
  • (no location specified)
Jan 30, 2023

Esophageal Cancer, Esophageal Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma by AJCC V8 Stage Trial (LBL-007,

Not yet recruiting
  • Esophageal Cancer
  • +2 more
  • (no location specified)
Aug 21, 2023

Fumarate Hydratase Deficient Renal Cell Carcinoma Trial (Tislelizumab, Lenvatinib)

Not yet recruiting
  • Fumarate Hydratase Deficient Renal Cell Carcinoma
  • (no location specified)
May 18, 2023

Colorectal Cancer Trial (Tislelizumab, Irinotecan Hydrochloride, cetuximab)

Not yet recruiting
  • Colorectal Cancer
  • Tislelizumab
  • +3 more
  • (no location specified)
Mar 23, 2023

Pancreatic Tumors Trial (Tislelizumab)

Not yet recruiting
  • Pancreatic Neoplasms
  • Tislelizumab
  • (no location specified)
Dec 26, 2022

Urothelial Carcinoma Trial in Shanghai (AZD4547, Tislelizumab)

Recruiting
  • Urothelial Carcinoma
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Mar 8, 2023

Upper Urinary Tract Urothelial Carcinoma, Kidney Preservation, HER-2 ADC Trial in Shanghai (RC48 Combined With Tislelizumab)

Recruiting
  • Upper Urinary Tract Urothelial Carcinoma
  • +3 more
  • RC48 Combined With Tislelizumab
  • Shanghai, Shanghai, China
    Ethics Committee of Shanghai Renji Hospital
Jun 20, 2023

Esophageal Squamous Cell Carcinoma Trial in Wuhan (Intensity-modulated radiotherapy (IMRT), Tislelizumab, Cisplatin)

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma
  • Intensity-modulated radiotherapy (IMRT)
  • +3 more
  • Wuhan, Hubei, China
    Renmin hosptial of Wuhan University
Jun 16, 2023

Esophageal Cancer Trial (Tislelizumab, Radiation, Paclitaxel)

Not yet recruiting
  • Esophageal Cancer
  • Tislelizumab
  • +3 more
  • (no location specified)
Nov 18, 2022

Metastatic Cervical Cancer Trial (Tislelizumab, Sitravatinib)

Not yet recruiting
  • Metastatic Cervical Cancer
  • (no location specified)
Jan 31, 2023

Hepatocellular Carcinoma Trial (Lenvatinib at a dose of 8 mg or 12 mg based on body weight + tislelizumab for one 21-day cycle)

Not yet recruiting
  • Hepatocellular Carcinoma
  • Lenvatinib at a dose of 8 mg or 12 mg based on body weight + tislelizumab for one 21-day cycle
  • (no location specified)
Jun 12, 2023